Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Tóm tắt
Từ khóa
Tài liệu tham khảo
Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem2003 ; 46 : 1116 –9.
Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res2003 ; 9 : 327 –37.
Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol2006 ; 24 : 16 –24.
Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA2006 ; 295 : 2516 –24.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe R, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). 2006 American Society of Clinical Oncology Annual Meeting Proceedings Pt I. Vol 24 (June 20 Suppl); 2006: LBA3.
Demitri GD, van Oosterom AT, Blackstein M, Garrett C, Shah M, Heinrich M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. 2005 American Society of Clinical Oncology Annual Meeting Proceedings Pt I of II. Vol 23 (June 1 Suppl); 2005:4000.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst2000 ; 92 : 205 –16.
Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, et al. Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene1997 ; 15 : 2687 –98.
Wang JF, Milosveski V, Schramek C, Fong GH, Becks GP, Hill DJ. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol1998 ; 157 : 5 –12.
Schoeffski P, Wolter P, Himpe U, Dychter SS, Baum CM, Prenen H, et al. Sunitinib-related thyroid dysfunction: a single-center retrospective and prospective evaluation. J Clin Oncol2006 ; 24 : 3092 .
Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med2006 ; 145 : 660 –4.
Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med1988 ; 318 : 1557 –63.
Franzke A, Peest D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol1999 ; 17 : 529 –33.
Weijl NI, Van der Harst D, Brand A, Kooy Y, Van Luxemburg S, Schroder J, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol1993 ; 11 : 1376 –83.